Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.

@article{Blay2015ManagementOG,
  title={Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.},
  author={Jean-Yves Blay and Paolo Giovanni Casali and Angelo P Dei Tos and Axel le Cesne and Peter Reichardt},
  journal={Oncology},
  year={2015},
  volume={89 1},
  pages={
          1-13
        }
}
Gastrointestinal stromal tumour (GIST), while relatively rare, is the most common mesenchymal tumour of the gastrointestinal tract. These tumours are largely resistant to cytotoxic chemotherapy and, in the past, were typically managed surgically. However, as a result of the identification of activating mutations in the proto-oncogene KIT and the development of compounds that inhibit the KIT receptor tyrosine kinase, GISTs have, in the last 14 years, become the archetype of a targeted agent… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA

  • M Daniels, I Lurkin, +16 authors R Schneider-Stock
  • Cancer Med
  • 2013

Reintroduction of imatinib in GIST

  • P Bümming, H Ahlman, J Andersson, JM Meis-Kindblom, LG Kindblom, B Nilsson
  • J Gastrointest Cancer
  • 2013

Continued sunitinib treatment after progressive disease ( PD ) in a worldwide treatment - use trial of patients ( pts ) with gastrointestinal stromal tumor ( abstract 1490 P )

  • T Reid
  • Ann Oncol
  • 2012

Similar Papers

Loading similar papers…